[go: up one dir, main page]

BR9914891A - Processos para aperfeiçoamento de cura de ferimento - Google Patents

Processos para aperfeiçoamento de cura de ferimento

Info

Publication number
BR9914891A
BR9914891A BR9914891-9A BR9914891A BR9914891A BR 9914891 A BR9914891 A BR 9914891A BR 9914891 A BR9914891 A BR 9914891A BR 9914891 A BR9914891 A BR 9914891A
Authority
BR
Brazil
Prior art keywords
wound healing
improvement processes
healing improvement
processes
chemo
Prior art date
Application number
BR9914891-9A
Other languages
English (en)
Inventor
Holger G Gassner
David A Sherris
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of BR9914891A publication Critical patent/BR9914891A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: <B>''PROCESSOS PARA APERFEIçOAMENTO DE CURA DE FERIMENTO''<D>. Um processo para tratamento de um paciente tendo um ferimento é descrito. O processo inclui administração de uma quantidade de um agente quimiodesnervante de modo que cura de ferimento é aperfeiçoada. O processo é ilustrado por detalhamento de diferenças médias dos escores das cicatrizes experimentais e controles emparelhadas através de três observadores.
BR9914891-9A 1998-10-27 1999-10-15 Processos para aperfeiçoamento de cura de ferimento BR9914891A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10568898P 1998-10-27 1998-10-27
PCT/US1999/024182 WO2000024419A1 (en) 1998-10-27 1999-10-15 Methods for enhancing wound healing

Publications (1)

Publication Number Publication Date
BR9914891A true BR9914891A (pt) 2001-07-17

Family

ID=22307238

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914891-9A BR9914891A (pt) 1998-10-27 1999-10-15 Processos para aperfeiçoamento de cura de ferimento

Country Status (12)

Country Link
US (3) US6447787B1 (pt)
EP (1) EP1128844B1 (pt)
JP (1) JP2002528421A (pt)
KR (1) KR20010089347A (pt)
CN (1) CN1324246A (pt)
AT (1) ATE314859T1 (pt)
AU (1) AU1706400A (pt)
BR (1) BR9914891A (pt)
CA (1) CA2347828A1 (pt)
DE (1) DE69929361T2 (pt)
MX (1) MXPA01004254A (pt)
WO (1) WO2000024419A1 (pt)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6276072B1 (en) * 1997-07-10 2001-08-21 Applied Materials, Inc. Method and apparatus for heating and cooling substrates
CA2347828A1 (en) * 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US7838008B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
EP1365800B1 (en) * 2000-06-28 2013-03-06 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
AU8466501A (en) 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
ES2312651T3 (es) * 2001-07-27 2009-03-01 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Toxina botulinum en el tratamiento o prevencion del acne.
EA006739B1 (ru) 2001-11-15 2006-04-28 Майкроу Элджи Корпорейшн Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
ATE426408T1 (de) * 2002-12-20 2009-04-15 Botulinum Toxin Res Ass Inc Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
WO2004078200A1 (en) * 2003-03-06 2004-09-16 Botulinum Toxin Research Associates, Inc. Selection of patients with increased responsiveness to botulinum toxin
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8871224B2 (en) 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050191321A1 (en) 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
CA2558408C (en) * 2004-03-03 2014-11-18 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
MXPA06012960A (es) 2004-05-07 2007-06-12 Phytotox Ltd Administracion transdermal de ficotoxinas.
CA2821239C (en) * 2004-05-07 2016-04-12 Phytotox Limited Phycotoxins and uses thereof
US6991789B2 (en) * 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US7179474B2 (en) * 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
US7429386B2 (en) * 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
EP1799254A1 (en) * 2004-09-27 2007-06-27 Merz Pharma GmbH & Co.KGaA Clostridial neurotoxins for use in tissue healing
US7897147B2 (en) * 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
GB0427642D0 (en) * 2004-12-16 2005-01-19 Renovo Ltd Information collection system
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
MX2007010673A (es) * 2005-03-03 2008-04-07 Revance Therapeutics Inc Composiciones y metodos para la aplicacion topica y el suministro transdermico de toxinas botulinicas.
CA2606315A1 (en) * 2005-05-05 2006-11-09 Phytotox Limited Use of phycotoxins in veterinary applications
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20060269574A1 (en) * 2005-05-31 2006-11-30 De Beer Johann F Method of repairing tendons by surgery
US8518414B2 (en) * 2005-11-17 2013-08-27 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
US20070178666A1 (en) * 2006-01-31 2007-08-02 Stats Chippac Ltd. Integrated circuit system with waferscale spacer system
US7414310B2 (en) * 2006-02-02 2008-08-19 Stats Chippac Ltd. Waferscale package system
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
NZ598039A (en) * 2006-12-29 2013-08-30 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
KR20090102833A (ko) * 2006-12-29 2009-09-30 레반스 테라퓨틱스, 아이엔씨. 역서열 ｈｉｖ-ｔａｔ 폴리펩티드를 이용한 수송 분자
PL2178549T3 (pl) 2007-07-26 2017-03-31 Revance Therapeutics, Inc. Peptyd przeciwdrobnoustrojowy i jego kompozycje
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
US20100028385A1 (en) * 2008-08-04 2010-02-04 Allergan, Inc. Treatment of excess cerumen secretion
PL2344329T3 (pl) 2008-10-02 2013-05-31 Mylan Inc Sposób wytwarzania wielowarstwowego laminatu przylepnego
CA2745657C (en) 2008-12-04 2022-06-21 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US20100184685A1 (en) * 2009-01-19 2010-07-22 Zavala Jr Gerardo Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein
CA2774951C (en) 2009-09-24 2014-12-16 Allergan, Inc. Method of treating osteoporosis with a neurotoxin
US20130123647A1 (en) 2011-05-03 2013-05-16 The Research Foundation Of State University Of New York Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections
US8697090B2 (en) 2011-05-05 2014-04-15 Allergan, Inc. Method of treating persistent genital arousal disorder with a neurotoxin
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
AU2012276512B2 (en) * 2011-06-27 2016-04-21 Sang Duck Kim Pharmaceutical composition for treating scars on the skin, and method for treating scars on the skin using same
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
WO2014066916A2 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US10076558B2 (en) * 2014-02-18 2018-09-18 Rnw Skn, Llc Prophylactic normalization of cutaneous wound repair
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
WO2016036618A1 (en) 2014-09-02 2016-03-10 American Silver, Llc Botulinum toxin and colloidal silver particles
WO2018038301A1 (en) 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
US10272024B1 (en) 2016-11-28 2019-04-30 Muhammad Mirza Methods for administration of cosmetic and medical agents
AU2018237205A1 (en) * 2017-03-22 2019-10-31 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
JP7604222B2 (ja) * 2017-03-22 2024-12-23 ボンチ インコーポレイテッド 治療用のボツリヌス神経毒素
EP3470054B1 (en) 2017-10-11 2023-09-20 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US10525111B2 (en) 2017-10-12 2020-01-07 Hugel, Inc. Microstructure formulation techniques for botulinum toxin
US10792400B2 (en) 2017-10-12 2020-10-06 Hugel Inc. Microstructure formulation techniques for botulinum toxin
US20190183987A1 (en) * 2017-12-18 2019-06-20 Bonti, Inc. Neurotoxins for use in minimizing scarring
LT3660509T (lt) 2018-11-29 2022-05-10 Hugel Inc. Ląstelių panaudojimu paremtas būdas botulino toksino aktyvumui nustatyti

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957996A (en) * 1971-12-08 1976-05-18 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic compositions
US3966934A (en) 1971-12-08 1976-06-29 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4029794A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition
US4029793A (en) 1973-06-12 1977-06-14 Astra Pharmaceutical Products, Inc. Synergistic local anesthetic compositions
US4080448A (en) * 1974-11-13 1978-03-21 Mirsky Louis H Method of treating cellular stress
JPS5594319A (en) * 1979-01-09 1980-07-17 Yoshio Otaka Drug for external use consisting of liver oil of swellfish
AU683275B2 (en) * 1993-06-10 1997-11-06 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DE69620888T2 (de) * 1996-11-27 2002-08-14 William J. Binder Neurotoxine zur Behandlung von Hauterkrankungen bei Säugetieren
WO1998043619A2 (en) * 1997-04-02 1998-10-08 The Regents Of The University Of California Method of local anesthesia
CA2347828A1 (en) * 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing

Also Published As

Publication number Publication date
CN1324246A (zh) 2001-11-28
US20050175637A1 (en) 2005-08-11
WO2000024419A1 (en) 2000-05-04
AU1706400A (en) 2000-05-15
US6447787B1 (en) 2002-09-10
EP1128844A1 (en) 2001-09-05
ATE314859T1 (de) 2006-02-15
EP1128844A4 (en) 2002-06-12
MXPA01004254A (es) 2002-04-24
WO2000024419A8 (en) 2001-03-15
JP2002528421A (ja) 2002-09-03
KR20010089347A (ko) 2001-10-06
EP1128844B1 (en) 2006-01-04
DE69929361D1 (de) 2006-03-30
DE69929361T2 (de) 2006-09-14
WO2000024419A9 (en) 2001-09-20
CA2347828A1 (en) 2000-05-04
US20060039930A2 (en) 2006-02-23
US20030036502A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
BR9914891A (pt) Processos para aperfeiçoamento de cura de ferimento
McLAUGHLIN Complex “locked” dislocation of the metacarpophalangeal joints
BR9600353A (pt) Processo para melhoria da segurança de dispositivos cirúrgicos implantáveis fixados em tecido ósseo e dispositivo cirúrgico
BR9916694A (pt) Composição de lenço facial e método de uso parasequestração de irritantes cutâneos de secreçãonasal
BR9712824A (pt) Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
BR9707325A (pt) Processo para o tratamento de um paciente afetado com uma doença mediada por il-1, composição farmacéutica e uso da mesma
BR9916197A (pt) Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral
BR9607601A (pt) Uso de ácido hialurÈnico para o tratamento de cistite intersticial
PT93935A (pt) Processo para a preparacao de uma composicao farmaceutica para o tratamento topico de acne vulgar contendo cetoconazol
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR9800660A (pt) Emulsão água-em-óleo sua utilização composição cosmética e/ou dermatológica processo de tratamento cosmético e utilzação de uma associação
BR0111591A (pt) Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes
BR0017331A (pt) Dispositivo para o tratamento de fratura de ossos e/ou para a fixação de implantes cirúrgicos
BR9913955A (pt) Composição oftalmológica confortável e de liberação sustentada e método para terapia ocular
BR9914735A (pt) Processo para tratamento de sépsia
BR9805318A (pt) Método para tratamento de infecções dos olhos com azitromicina.
BR9808303A (pt) O uso de levobupivacaìna na cirurgia facial
Krettek et al. The role of supplemental lag-screw fixation for open fractures of the tibial shaft treated with external fixation.
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
BR9809673A (pt) Derivados de triptolida úteis no tratamento de doenças autoimunes
KR930019224A (ko) 유산 위험 치료제
BR0012661A (pt) Métodos de tratamento e métodos de triagem de drogas
BR9005717A (pt) Agente para o tratamento de couros e peles e processo para preparacao de couros e peles&#34;wet-white&#34;,aplicacao e os ditos couros e peles&#34;wet-white&#34;assim obtidos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.